Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence

Current Opinion in Pharmacology

Volumn 21, Issue , 2015, Pages 95-104

  Stasch, Johannes Peter ^a,b   Schlossmann, Jens ^c   Hocher, Berthold ^d  

^a BAYER PHARMA AG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF POTSDAM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ATACIGUAT; BI 703704; CINACIGUAT; CYCLIC GMP; GSK 2181236A; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; LIFICIGUAT; NELOCIGUAT; NITRIC OXIDE; RIOCIGUAT; UNCLASSIFIED DRUG; VERICIGUAT; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; CELL RECEPTOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEART FUNCTION; HEART INJURY; HEART OUTPUT; HEART PROTECTION; HEART STROKE VOLUME; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DISORDER; NONHUMAN; PULMONARY HYPERTENSION; RENAL PROTECTION; URINARY EXCRETION; URINE VOLUME; VASCULAR DISEASE; VASCULAR RESISTANCE; ANIMAL; CHRONIC KIDNEY FAILURE; KIDNEY; METABOLISM;

ANIMALS; GUANYLATE CYCLASE; KIDNEY; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84921940831     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.12.014     Document Type: Review

References (56)

1. V. Jha, G. Garcia-Garcia, K. Iseki, Z. Li, S. Naicker, B. Plattner, R. Saran, A.Y. Wang, and C.W. Yang Chronic kidney disease: global dimension and perspectives Lancet 382 2013 260 272
2. G. Ruiz-Hurtado, and L.M. Ruilope Does cardiovascular protection translate into renal protection? Nat Rev Cardiol 11 2014 742 746
3. K.U. Eckardt, J. Coresh, O. Devuyst, R.J. Johnson, A. Kottgen, A.S. Levey, and A. Levin Evolving importance of kidney disease: from subspecialty to global health burden Lancet 382 2013 158 169
4. G. Remuzzi, A. Benigni, F.O. Finkelstein, J.P. Grunfeld, D. Joly, I. Katz, Z.H. Liu, T. Miyata, N. Perico, and B. Rodriguez-Iturbe Kidney failure: aims for the next 10 years and barriers to success Lancet 382 2013 353 362
5. Y. Liu Renal fibrosis: new insights into the pathogenesis and therapeutics Kidney Int 69 2006 213 217
6. P.A. Sarafidis, N. Khosla, and G.L. Bakris Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 2007 12 26
7. H.T. Yu Progression of chronic renal failure Arch Intern Med 163 2003 1417 1429
8. M.R. Weir Progressive renal and cardiovascular disease: optimal treatment strategies Kidney Int 62 2002 1482 1492
9. S. Geschka, A. Kretschmer, Y. Sharkovska, O.V. Evgenov, B. Lawrenz, A. Hucke, B. Hocher, and J.P. Stasch Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats PLoS ONE 6 2011 e21853
10. B. Nossaman, E. Pankey, and P. Kadowitz Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications Crit Care Res Pract 2012 2012 290805
11. Y. Wang-Rosenke, H.H. Neumayer, and H. Peters NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target Curr Med Chem 15 2008 1396 1406
12. K.S. Hodgkins, and H.W. Schnaper Tubulointerstitial injury and the progression of chronic kidney disease Pediatr Nephrol 27 2012 901 909
13. K. Ito, J. Chen, S.V. Seshan, J.J. Khodadadian, R. Gallagher, C.M. El, E.D. Vaughan Jr., D.P. Poppas, and D. Felsen Dietary arginine supplementation attenuates renal damage after relief of unilateral ureteral obstruction in rats Kidney Int 68 2005 515 528
14. B.C. Kone Nitric oxide in renal health and disease Am J Kidney Dis 30 1997 311 333
15. P.S. Modlinger, C.S. Wilcox, and S. Aslam Nitric oxide, oxidative stress, and progression of chronic renal failure Semin Nephrol 24 2004 354 365
16. M. Noris, and G. Remuzzi Physiology and pathophysiology of nitric oxide in chronic renal disease Proc Assoc Am Physicians 111 1999 602 610
17. R.J. Schmidt, and C. Baylis Total nitric oxide production is low in patients with chronic renal disease Kidney Int 58 2000 1261 1266
18. S.S. Prabhakar Role of nitric oxide in diabetic nephropathy Semin Nephrol 24 2004 333 344
19. F. Reis, P. Rocha-Pereira, L.E. Teixeira de, B. Parada, S. Baptista, A. Figueiredo, A. Santos-Silva, C. Costa-Almeida, A. Mota, and F. Teixeira Oxidative stress in cyclosporine-induced hypertension: evidence of beneficial effects or tolerance development with nitrate therapy Transplant Proc 39 2007 2494 2500
20. L. Ribeiro, de Assuncao e Silva, R.S. Kurihara, N. Schor, E. Mieko, and S. Higa Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents Kidney Int 65 2004 589 596
21. C. Zoccali Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension J Am Soc Nephrol 17 2006 S61 S63
22. M. Dautzenberg, A. Kahnert, J.P. Stasch, and A. Just Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat Am J Physiol Renal Physiol 307 2014 F1003 F1012
23. R.D. Toto Treatment of hypertension in chronic kidney disease Semin Nephrol 25 2005 435 439
24. J.P. Stasch, P. Pacher, and O.V. Evgenov Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease Circulation 123 2014 2263 2273
25. M. Follmann, N. Griebenow, M.G. Hahn, I. Hartung, F.J. Mais, J. Mittendorf, M. Schafer, H. Schirok, J.P. Stasch, and F. Stoll The chemistry and biology of soluble guanylate cyclase stimulators and activators Angew Chem Int Ed Engl 52 2013 9442 9462
26. E. Schinner, A. Schramm, F. Kees, F. Hofmann, and J. Schlossmann The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis Kidney Int 84 2013 1198 1206
27. L. Hoffmann, A. Kretschmer, B. Lawrenz, A. Hucke, B. Hocher, and J.-P. Stasch Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension PLoS ONE 6 2011 e23596
28. G. Boerrigter, L.C. Costello-Boerrigter, A. Cataliotti, H. Lapp, J.P. Stasch, and J.C. Burnett Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure Hypertension 49 2007 1128 1133
29. M.H. Costell, N. Ancellin, R.E. Bernard, S. Zhao, J.J. Upson, L.A. Morgan, K. Maniscalco, A.R. Olzinski, V.L. Ballard, and K. Herry Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress Front Pharmacol 3 2012 128
30. B. Hohenstein, C. Daniel, A. Wagner, J.P. Stasch, and C. Hugo Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis Am J Physiol Renal Physiol 288 2005 F685 F693
31. E.S. Jones, B.K. Kemp-Harper, J.P. Stasch, H.H.H.W. Schmidt, and R.E. Widdop Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension BMC Pharmacol 9 Suppl. 1 2009 P29
32. P. Kalk, M. Godes, K. Relle, C. Rothkegel, A. Hucke, J.P. Stasch, and B. Hocher NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy Br J Pharmacol 148 2006 853 859
33. H. Masuyama, T. Tsuruda, J. Kato, T. Imamura, Y. Asada, J.P. Stasch, K. Kitamura, and T. Eto Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats Hypertension 48 2006 972 978
34. H. Masuyama, T. Tsuruda, Y. Sekita, K. Hatakeyama, T. Imamura, J. Kato, Y. Asada, J.P. Stasch, and K. Kitamura Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart Hypertens Res 32 2009 597 603
35. I.M. Ott, M.L. Alter, W.K. von, A. Kretschmer, O. Tsuprykov, Y. Sharkovska, K. Krause-Relle, J. Raila, A. Henze, and J.P. Stasch Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade PLoS ONE 7 2012 e42623
36. H. Peters, Y. Wang, T. Loof, S. Martini, S. Kron, S. Kramer, and H.H. Neumayer Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis Kidney Int 66 2004 2224 2236
37. A. Schafer, D. Fraccarollo, L. Werner, and J. Bauersachs Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure Pharmacol Res 62 2010 432 438
38. Y. Sharkovska, P. Kalk, B. Lawrenz, M. Godes, L.S. Hoffmann, K. Wellkisch, S. Geschka, K. Relle, B. Hocher, and J.P. Stasch Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models J Hypertens 28 2010 1666 1675
39. J.P. Stasch, E.M. Becker, C. Alonso-Alija, H. Apeler, K. Dembowsky, A. Feurer, R. Gerzer, T. Minuth, E. Perzborn, and U. Pleiss NO-independent regulatory site on soluble guanylate cyclase Nature 410 2001 212 215
40. J.P. Stasch, K. Dembowsky, E. Perzborn, E. Stahl, and M. Schramm Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator BAY 41-8543: in vivo studies Br J Pharmacol 135 2002 344 355
41. Y. Wang, S. Kramer, T. Loof, S. Martini, S. Kron, H. Kawachi, F. Shimizu, H.H. Neumayer, and H. Peters Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis Kidney Int 68 2005 47 61
42. Y. Wang, S. Kramer, T. Loof, S. Martini, S. Kron, H. Kawachi, F. Shimizu, H.H. Neumayer, and H. Peters Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition Am J Physiol Renal Physiol 290 2006 F167 F176
43. Y. Wang-Rosenke, A. Mika, D. Khadzhynov, T. Loof, H.H. Neumayer, and H. Peters Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction J Urol 188 2012 316 323
44. M. Zanfolin, R. Faro, E.G. Araujo, A.M. Guaraldo, E. Antunes, and N.G. De Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic l-NAME treatment in rats J Cardiovasc Pharmacol 47 2006 391 395
45. Y. Wang-Rosenke, A. Mika, D. Khadzhynov, T. Loof, H.H. Neumayer, and H. Peters Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction J Urol 186 2011 1142 1149
46. H.A. Ghofrani, A.M. D'Armini, F. Grimminger, M.M. Hoeper, P. Jansa, N.H. Kim, E. Mayer, G. Simonneau, M.R. Wilkins, and A. Fritsch Riociguat for the treatment of chronic thromboembolic pulmonary hypertension N Engl J Med 369 2013 319 329
47. H.A. Ghofrani, N. Galiè, F. Grimminger, E. Grünig, M. Humbert, Z.C. Jing, A.M. Keogh, D. Langleben, M.O. Kilama, and A. Fritsch Riociguat for the treatment of pulmonary arterial hypertension N Engl J Med 369 2013 330 340
48. J.P. Stasch, and O.V. Evgenov Soluble guanylate cyclase stimulators in pulmonary hypertension Handb Exp Pharmacol 218 2013 279 313
49. Fibig A: Bayer Pharmaceuticals Handout. San Francisco, USA 2013
50. S.J. Greene, M. Gheorghiade, B.A. Borlaug, B. Pieske, M. Vaduganathan, J.C. Burnett Jr., L. Roessig, J.P. Stasch, S.D. Solomon, and W.J. Paulus The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction J Am Heart Assoc 2 2013 e000536
51. M. Gheorghiade, C.N. Marti, H.N. Sabbah, L. Roessig, S.J. Greene, M. Bohm, J.C. Burnett, U. Campia, J.G. Cleland, and S.P. Collins Soluble guanylate cyclase: a potential therapeutic target for heart failure Heart Fail Rev 18 2013 123 134
52. B. Pieske, J. Butler, G. Filippatos, C. Lam, A.P. Maggioni, P. Ponikowski, S. Shah, S. Solomon, E. Kraigher-Krainer, and E.T. Samano Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) Eur J Heart Fail 16 2014 1026 1038
53. Fang L, Radovits T, Merkely B, Mozes M, Rosivall L, Kokeny G: The Soluble Guanylate Cyclase Inhibitor Cinaciguat Attenuates Nephropathy in Diabetic Rats. Paris, France 2014.
54. K. Benz, S.R. Orth, A. Simonaviciene, W. Linz, U. Schindler, H. Rutten, and K. Amann Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage Kidney Blood Press Res 30 2007 224 233
55. H. Chen, P. Harrison, K.A. Lincoln, S. Goldrick, N.F. Brown, K. Gueneva-Boucheva, H.S. Qian, S.S. Pullen, G.A. Reinhart, and C. Boustany Sustained beneficial effects of a soluble guanylate cyclase activator on diabetic nephropathy ASN Kidney Week Philadelphia, PA, USA, November 11-16 2014 FR-FR293 [Abstract]
56. P. Harrison, H. Chen, K.A. Lincoln, H. Wang, N.F. Brown, H. Clifford, H.S. Qian, G.A. Reinhart, D. Wong, S. Sarko, J. Ginn, J. Brenneman, T. Bosanac, R.M. Fryer, J.G. Richman, C. Boustany, and S.S. Pullen A soluble guanylate cyclase activatior protects from diabetic nephropathy in the ZSF-1 rat ASN Kidney Week Philadelphia, PA, USA, November 11-16 2014 TH-TH474 [Abstract]